Tango Therapeutics Proposes $500M Equity Offering With $75M Overallotment Option
TNGX•Tango Therapeutics launched a $500 million underwritten public offering of stock and granted underwriters a 30-day option to purchase up to an additional $75 million of shares. The offering uses a previously filed shelf registration and is subject to market conditions with no assurance of completion or final terms.
1. Proposed Offering Structure
Tango Therapeutics intends to sell $500 million of common stock in an underwritten public offering and has granted the underwriters a 30-day option to purchase up to an additional $75 million of shares on the same terms.
2. Registration and Market Conditions
The offering is being conducted under a previously filed effective shelf registration statement and remains subject to prevailing market conditions, with no guarantee of completion or fixed terms.
3. Joint Bookrunning Managers
J.P. Morgan, Leerink Partners, Cantor Fitzgerald and Stifel are serving as joint bookrunning managers for the offering, coordinating the sale and allocation of shares.
4. Company Background
Tango Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision cancer medicines by leveraging synthetic lethality to identify novel therapeutic targets.
